BUY Glenmark Pharmaceuticals — Motilal Oswal
byMotilal OswalHorizon: NA (inferred 1 year)1 Jun 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
10 midcap stocks with over 150% profit growth in Q1FY27
NewsEt-Markets·6 Sept · today
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·4 Sept · 2d ago
Is Nifty set for a breakout? Analysts see signs of a shift ahead
NewsEt-Markets·31 Aug · 6d ago
Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.
BSE · Company Update·21 Aug · 2w ago
Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.
BSE · Company Update·20 Aug · 2w ago
Buy, Sell Or Hold: Vishal Mega Mart, HDFC Bank, Shriram Finance, Ather Energy And Glenmark Pharma — Ask Profit
NewsNdtv-Profit·31 Aug · 6d ago
Corporate Actions This Week: Coal India, ONGC, Glenmark Pharma, GAIL, Nirlon — Check Full List Here
NewsNdtv-Profit·30 Aug · 1w ago
Glenmark Pharma, Mastek, Triveni Engineering Dividends: Last Day To Buy Shares To Qualify
NewsNdtv-Profit·28 Aug · 1w ago
Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s
BSE · Company Update·11 Aug · 4w ago
Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits
NewsCnbc-Tv18·12 Aug · 4w ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock
Advisor consensus · same horizon·3 Feb · 7mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

